Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

By LabMedica International staff writers
Posted on 21 Jan 2025

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. More...

Late-stage detection often results in major surgeries, such as bladder removal and the use of an artificial bladder or urine pouch, which significantly impact the patient’s quality of life. However, current urine test kits are not very sensitive, and cystoscopy, which involves inserting a catheter into the urethra to examine the bladder, is both painful and inconvenient. This situation highlights the critical need for a simple yet reliable diagnostic method for patients. Now, a new urine-based diagnostic kit has been developed that can accurately detect bladder cancer biomarkers without the need for preprocessing the urine samples.

This innovative diagnostic tool was developed by a research team at the Korea Institute of Science and Technology (KIST, Seoul, Republic of Korea), using a method based on water and oil layering to detect biomarkers of bladder cancer. Detecting biomarkers in urine has been challenging due to their low concentration and interference from impurities like hematuria. The newly designed kit overcomes these obstacles by employing a mechanism in which a film bonded to the biomarker breaks apart, releasing a buoyant signal carrier that moves to the oil layer and emits a detectable signal. This design eliminates interference from impurities like hematuria and amplifies the signal, allowing for accurate biomarker detection. In clinical trials involving 80 patients and 25 healthy individuals, conducted with a double-blind approach, the diagnostic kit achieved a sensitivity of 88.8%, which is a substantial improvement over the mere 20% sensitivity of existing commercial tests.

Importantly, while traditional methods are almost unable to diagnose early-stage bladder cancer, the new kit is effective in identifying even early-stage cases. This diagnostic tool offers a groundbreaking approach for the early detection of bladder cancer through a simple, non-invasive urine test. It is expected to reduce the reliance on cystoscopy, improve survival rates through early detection, and enhance patients’ quality of life. Building on these promising results, the research team plans to develop products suitable for mass use in comprehensive medical centers and for easy home application.

“This study demonstrates the potential for early bladder cancer diagnosis using a simple diagnostic kit, reducing the need for unnecessary cystoscopies,” said Dr. Youngdo Jeong from KIST who led the research team.

Related Links:
KIST


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.